Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02267642 · ClinicalTrials.gov registry record · Phase 2

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

A Phase 2 study of Psoriatic Arthritis, sponsored by AbGenomics B.V Taiwan Branch.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
7
Study locations

NCT02267642 is a Phase 2 study of Psoriatic Arthritis that has completed, run by AbGenomics B.V Taiwan Branch. The registered enrollment target is 20 participants, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02267642, a Phase 2 study of Psoriatic Arthritis, has completed, sponsored by AbGenomics B.V Taiwan Branch.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
7
Study locations

Study Summary

To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.

Conditions Studied

Interventions

  • BIOLOGICAL AbGn-168H

Study Locations (7)

California

  • UC San Diego - La Jolla
  • Stanford University - Palo Alto

Florida

  • Sarasota Arthritis Research Center - Sarasota

Illinois

  • Northwestern University - Chicago

Michigan

  • Justus J. Fiechtner, MD, PC - Lansing

Texas

  • Metroplex Clinical Research Center, LLC - Dallas

Washington

  • Seattle Rheumatology Associates/Swedish Clinical Research - Seattle

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-01
Est. Completion 2016-01
Phase Phase 2

Sponsor

AbGenomics B.V Taiwan Branch

6 total trials

What the Registry Record Tells You About NCT02267642

The ClinicalTrials.gov registry entry for NCT02267642 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is AbGenomics B.V Taiwan Branch, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which AbGn-168H is the first listed.

NCT02267642 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT02267642 about?

NCT02267642 is a clinical study titled "A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis". To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.

What is the current status of trial NCT02267642?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-01. Estimated completion is 2016-01.

What conditions does trial NCT02267642 study?

This clinical trial studies the following conditions: Psoriatic Arthritis.

What interventions are being tested in trial NCT02267642?

The interventions under investigation include: AbGn-168H (BIOLOGICAL).

Who is sponsoring clinical trial NCT02267642?

This trial is sponsored by AbGenomics B.V Taiwan Branch, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02267642 being conducted?

This trial has 7 study locations across California, Florida, Illinois, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psoriatic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.